UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|----------------------------------|--------------------------------|----------------------|---------------------|------------------|
| 10/594,046 | 09/25/2006 | Nnochiri N. Ekwuribe | 014811-673.119US | 8968 |
| | 7590 08/07/200 N ALLEN PLLC | EXAMINER | | |
| P.O. BOX 1370 | | SPIVACK, PHYLLIS G | | |
| Research Triangle Park, NC 27709 | | | ART UNIT | PAPER NUMBER |
| | | | 1614 | |
| | | | | |
| | | | MAIL DATE | DELIVERY MODE |
| | | | 08/07/2008 | PAPER |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

| Office Action Summary | | Application No. | Applicant(s) | | | | |
|--|--|--|------------------------------|--|--|--|--|
| | | 10/594,046 | EKWURIBE ET AL. | | | | |
| | | Examiner | Art Unit | | | | |
| | | Phyllis G. Spivack | 1614 | | | | |
| Period fo | The MAILING DATE of this communication app or Reply | ears on the cover sheet with the c | orrespondence address | | | | |
| A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). | | | | | | | |
| Status | | | | | | | |
| 1) 🛛 | Responsive to communication(s) filed on <u>Septe</u> | ember 7 and 26. 2008. | | | | | |
| , | · · · · · · · · · · · · · · · · · · · | action is non-final. | | | | | |
| ′= | Since this application is in condition for allowance except for formal matters, prosecution as to the merits is | | | | | | |
| ,— | closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. | | | | | | |
| Dispositi | on of Claims | | | | | | |
| 4)🖂 | Claim(s) <u>1-30</u> is/are pending in the application. | | | | | | |
| , | 4a) Of the above claim(s) is/are withdrawn from consideration. | | | | | | |
| | 5) Claim(s) is/are allowed. | | | | | | |
| • | 6)⊠ Claim(s) <u>1-30</u> is/are rejected. | | | | | | |
| | Claim(s) is/are objected to. | | | | | | |
| | Claim(s) are subject to restriction and/or | r election requirement. | | | | | |
| | on Papers | · | | | | | |
| | · | r | | | | | |
| 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. | | | | | | | |
| | | | | | | | |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). | | | | | | | |
| Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. | | | | | | | |
| , — | ınder 35 U.S.C. § 119 | animor. Note the attached Cines | 7.00.017 01 1011117 1 0 102. | | | | |
| | <u>-</u> | | | | | | |
| 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. | | | | | | | |
| 2) Notic 3) Inforr | e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date <u>9-14-07</u> . | 4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other: | ate | | | | |

Applicants' Amendment filed September 7, 2007 and Supplemental Response filed September 26, 2007 are acknowledged. Claim 31 is canceled. Claims 1-30 remain under consideration.

An Information Disclosure Statement filed September 14, 2007 is acknowledged and has been reviewed. Each reference must have a publication date.

Applicants' arguments have been fully considered and are persuasive in part.

Rejections and objections not reiterated from previous Office Actions are hereby withdrawn. The following objections and rejection constitute the only objections and rejection presently applied to the instant claims.

In the last Office Action the disclosure was objected to for the following informality: Claim 2 is incomplete. The claim ends with "agent selected from the group consisting of: steroids, antibiotics,." It appears other agents were intended, or the term "and" should appear between the recited agents.

No response is noted, and the objection of record is maintained.

The specification is objected to as failing to provide proper antecedent basis for the claimed subject matter. See 37 CFR 1.75(d)(1) and MPEP § 608.01(o). Correction of the following is required: Claim 30 is drawn to a method of treating an inflammatory **gastro**intestinal condition. There is no antecedent basis in the specification for inflammatory diseases of the stomach, or any organ of the gastrointestinal tract, other than the colon.

Applicants' discussion in the Amendment filed September 14, 2007 directed to the filing of three terminal disclaimers is noted. However, regrettably, only the required fee for the filing of three terminal disclaimers is apparent to the Examiner. It appears the paperwork, if properly submitted, has not been scanned. Accordingly, Applicants are urged to file the three terminal disclaimers according to the proper procedure or to contact supervisory LIE Brenda Gray at telephone number 571-272-0528 for direction as to having the submitted paperwork scanned.

The rejection of claims 1-29 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-5 of U.S. Patent No. 7,119,119 is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of the patent are drawn to pharmaceutical compositions comprising the two therapeutic agents 4-aminophenylacetic acid and 5-aminosalicylic acid.

No claim is allowed.

THIS ACTION IS MADE FINAL. Applicants are reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this Final Action is set to expire THREE MONTHS from the mailing date of this Action. In the event a first reply is filed within TWO MONTHS of the mailing date of this Final Action and the Advisory Action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the

Art Unit: 1614

shortened statutory period will expire on the date the Advisory Action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the Advisory Action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this Final Action.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Phyllis G. Spivack whose telephone number is 571-272-0585. The Examiner can normally be reached from 10:30 to 7 PM.

If attempts to reach the Examiner by telephone are unsuccessful after one business day, the Examiner's supervisor, Ardin Marschel, can be reached 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

August 3, 2008

/Phyllis G. Spivack/

Primary Examiner, Art Unit 1614

Application/Control Number: 10/594,046

Page 5

Art Unit: 1614